Application of berberine on treating type 2 diabetes mellitus

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Pang, Bing ^a   Zhao, Lin Hua ^a   Zhou, Qiang ^b   Zhao, Tian Yu ^a   Wang, Han ^a   Gu, Cheng Juan ^a   Tong, Xiao Lin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

8,8 DIMETHYLDIHYDROBERBERINE; ANTIDIABETIC AGENT; BERBERINE; BERBERINE DERIVATIVE; DIHYDROBERBERINE; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLADDER CANCER; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CONSTIPATION; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; EDEMA; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE METABOLISM; GLYCOLYSIS; GOOD CLINICAL PRACTICE; HERB; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE ABSORPTION; INTESTINE FLORA; LIPID METABOLISM; LIVER; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84925679461     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/905749     Document Type: Review

References (108)

1. International Diabetes Federation, IDF Diabetes Altas Globally, IDF, 6th edition, 2013.
2. Z. J. Wang, J. Wang, and P. Chan, "Treating type 2 diabetes mellitus with traditional Chinese and Indian medicinal herbs," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 343594, 17 pages, 2013.
3. W. D. Xie, Y. N. Zhao, and Y. O. Zhang, "Traditional Chinese medicines in treatment of patients with type 2 diabetes mellitus," Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 726723, 13 pages, 2011.
4. P. Zimmet, K. G.M.M. Alberti, and J. Shaw, "Global and societal implications of the diabetes epidemic," Nature, vol. 414, no. 6865, pp. 782-787, 2001.
5. E. Asante, "Interventions to promote treatment adherence in type 2 diabetes mellitus," British Journal of Community Nursing, vol. 18, no. 6, pp. 267-274, 2013.
6. A. A. Agarwal, P. R. Jadhav, and Y. A. Deshmukh, "Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients," Journal of Basic and Clinical Pharmacy, vol. 5, no. 3, pp. 79-83, 2014.
7. J. Nagpal and A. Bhartia, "Quality of diabetes care in the middle- and high-income group populace: the Delhi Diabetes Community (DEDICOM) survey," Diabetes Care, vol. 29, no. 11, pp. 2341-2348, 2006.
8. P. F. Valerón and P. L. de Pablos-Velasco, "Limitations of insulindependent drugs in the treatment of type 2 diabetes mellitus," Medicina Clínica, vol. 141, supplement 2, pp. 20-25, 2013.
9. Authority of the Board of the American Socitey of Health- System Pharamcists, AHFS Drug Information, American Hospital Formulary Service, Bethesda, Md, USA, 2012.
10. M. Hanefeld, X. Ganz, and C. Nolte, "Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2," Herz, vol. 39, no. 3, pp. 312-319, 2014.
11. H. B. Shi and Q. Cai, "Summary on adverse reactions of antidiabetic drugs," Zhong Guo Yao Wu Jing Jie, vol. 10, no. 3, pp. 159-162, 2013.
12. S. El-Kaissi and S. Sherbeeni, "Pharmacological management of type 2 diabetes mellitus: an update," Current Diabetes Reviews, vol. 7, no. 6, pp. 392-405, 2011.
13. W. L. Li, H. C. Zheng, J. Bukuru, and N. De Kimpe, "Natural medicines used in the traditional Chinese medical system for therapy of diabetesmellitus," Journal of Ethnopharmacology, vol. 92, no. 1, pp. 1-21, 2004.
14. Q. Wang, "The present situation of TCMtreatment for diabetes and its researches," Journal of Traditional ChineseMedicine, vol. 23, no. 1, pp. 67-73, 2003.
15. T.-F. Tzeng, S.-S. Liou, and I.-M. Liu, "The selected traditional chinese medicinal formulas for treating diabetic nephropathy: perspective of modern science," Journal of Traditional and Complementary Medicine, vol. 3, no. 3, pp. 152-158, 2013.
16. P. K. Prabhakar and M. Doble, "Mechanism of action of natural products used in the treatment of diabetes mellitus," Chinese Journal of Integrative Medicine, vol. 17, no. 8, pp. 563-574, 2011.
17. H. Dong, N. Wang, L. Zhao, and F. Lu, "Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 591654, 12 pages, 2012.
18. H. Dong, Y. Zhao, L. Zhao, and F. Lu, "The effects of berberine on blood lipids: a systemic reviewandmeta-analysis of randomized controlled trials," PlantaMedica, vol. 79, no. 6, pp. 437-446, 2013.
19. G. Derosa, P. Maffioli, and A. F. G. Cicero, "Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials," Expert Opinion on BiologicalTherapy, vol. 12, no. 8, pp. 1113-1124, 2012.
20. I. P. Singh and S. Mahajan, "Berberine and its derivatives: a patent review (2009-2012)," Expert Opinion on Therapeutic Patents, vol. 23, no. 2, pp. 215-231, 2013.
21. P. R. Vuddanda, S. Chakraborty, and S. Singh, "Berberine: a potential phytochemical with multispectrum therapeutic activities," Expert Opinion on Investigational Drugs, vol. 19, no. 10, pp. 1297-1307, 2010.
22. Q. M. Chen and M. Z. Xie, "Studies on the hypoglycemic effect of Coptis chinensis and berberine," Acta Pharmaceutica Sinica, vol. 21, no. 6, pp. 401-406, 1986 (Chinese).
23. Q. Zhang, X. Xiao, K. Feng et al., "Berberine moderates glucose and lipid metabolism through multipathway mechanism," Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 924851, 10 pages, 2011.
24. J. Yang, J. Yin, H. Gao, L. Xu, Y. Wang, and M. Li, "Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients," Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 363845, 9 pages, 2012.
25. W.-H. Chueh and J.-Y. Lin, "Berberine, an isoquinoline alkaloid in herbal plants, protects pancreatic islets and serum lipids in nonobese diabetic mice," Journal of Agricultural and Food Chemistry, vol. 59, no. 14, pp. 8021-8027, 2011.
26. W. H. Chueh and J. Y. Lin, "Protective effect of berberine on serum glucose levels in non-obese diabetic mice," International Immunopharmacology, vol. 12, no. 3, pp. 534-538, 2012.
27. W.-J. Kong, H. Zhang, D.-Q. Song et al., "Berberine reduces insulin resistance through protein kinase C-dependent upregulation of insulin receptor expression," Metabolism: Clinical and Experimental, vol. 58, no. 1, pp. 109-119, 2009.
28. S. H. Kim, E.-J. Shin, E.-D. Kim, T. Bayaraa, S. C. Frost, and C.- K. Hyun, "Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes," Biological and Pharmaceutical Bulletin, vol. 30, no. 11, pp. 2120-2125, 2007.
29. B.-S. Ko, S. B. Choi, S. K. Park, J. S. Jang, Y. E. Kim, and S. Park, "Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma," Biological and Pharmaceutical Bulletin, vol. 28, no. 8, pp. 1431-1437, 2005.
30. W. Zhang, Y.-C. Xu, F.-J. Guo, Y. Meng, and M.-L. Li, "Antidiabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus," Chinese Medical Journal, vol. 121, no. 21, pp. 2124-2128, 2008.
31. C. Chen, Y. Zhang, and C. Huang, "Berberine inhibits PTP1B activity and mimics insulin action," Biochemical and Biophysical Research Communications, vol. 397, no. 3, pp. 543-547, 2010.
32. Y. S. Lee, W. S. Kim, K. H. Kim et al., "Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states," Diabetes, vol. 55, no. 8, pp. 2256-2264, 2006.
33. J.-T. Hwang, D. Y. Kwon, and S. H. Yoon, "AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols," New Biotechnology, vol. 26, no. 1-2, pp. 17-22, 2009.
34. B. B. Kahn, T. Alquier, D. Carling, and D. G. Hardie, "AMPactivated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism," Cell Metabolism, vol. 1, no. 1, pp. 15-25, 2005.
35. J. Yin, Z. Gao, D. Liu, Z. Liu, and J. Ye, "Berberine improves glucosemetabolism through induction of glycolysis,"TheAmerican Journal of Physiology - Endocrinology and Metabolism, vol. 294, no. 1, pp. E148-E156, 2008.
36. Z. Cheng, T. Pang, M. Gu et al., "Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK," Biochimica et Biophysica Acta - General Subjects, vol. 1760, no. 11, pp. 1682-1689, 2006.
37. Y. Yu, L. Liu, X. Wang, X. Liu, L. Xie, and G. Wang, "Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies," Biochemical Pharmacology, vol. 79, no. 7, pp. 1000-1006, 2010.
38. S.-S. Lu, Y.-L. Yu, H.-J. Zhu et al., "Berberine promotes glucagon- like peptide-1 (7-36) amide secretion in streptozotocininduced diabetic rats," Journal of Endocrinology, vol. 200, no. 2, pp. 159-165, 2009.
39. X. Xia, J. Yan, Y. Shen et al., "Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis," PLoS ONE, vol. 6, no. 2, Article ID e16556, 2011.
40. Z.-Q. Wang, F.-E. Lu, S.-H. Leng et al., "Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity," World Journal of Gastroenterology, vol. 14, no. 39, pp. 6004-6011, 2008.
41. J. Berger and D. E. Moller, "The mechanisms of action of PPARs," Annual Review of Medicine, vol. 53, pp. 409-435, 2002.
42. J. Y. Zhou, S. W. Zhou, K. B. Zhang et al., "Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats," Biological and Pharmaceutical Bulletin, vol. 31, no. 6, pp. 1169-1176, 2008.
43. K. Schoonjans, B. Staels, and J. Auwerx, "The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation," Biochimica et Biophysica Acta: Lipids and Lipid Metabolism, vol. 1302, no. 2, pp. 93-109, 1996.
44. C. Huang, Y. Zhang, Z. Gong et al., "Berberine inhibits 3T3- L1 adipocyte differentiation through the PPARγ pathway," Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 571-578, 2006.
45. J. Yin, H. Zhang, and J. Ye, "Traditional Chinese medicine in treatment of metabolic syndrome," Endocrine, Metabolic and Immune Disorders - Drug Targets, vol. 8, no. 2, pp. 99-111, 2008.
46. L. Liu, Y.-L. Yu, J.-S. Yang et al., "Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study," Naunyn- Schmiedeberg's Archives of Pharmacology, vol. 381, no. 4, pp. 371-381, 2010.
47. L. Liu, Y. Deng, S. Yu, S. Lu, L. Xie, and X. Liu, "Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats," Pharmazie, vol. 63, no. 5, pp. 384-388, 2008.
48. J. Han, H. Lin, and W. Huang, "Modulating gut microbiota as an anti-diabetic mechanism of berberine," Medical Science Monitor, vol. 17, no. 7, pp. RA164-RA167, 2011.
49. G. S. Hotamisligil, "Inflammation and metabolic disorders," Nature, vol. 444, no. 7121, pp. 860-867, 2006.
50. P. D. Cani and N. M. Delzenne, "The role of the gut microbiota in energy metabolism andmetabolic disease," Current Pharmaceutical Design, vol. 15, no. 13, pp. 1546-1558, 2009.
51. Z. X. Li, X. H. Wang, J. H. Zhao et al., "Studies on in vitro antibacterial activity of Coptis chinensis against 252 strains inclinic with muellerhinton agar," Zhong Cao Yao, vol. 32, pp. 337-339, 2001.
52. R. S. Iwazaki, E. H. Endo, T. Ueda-Nakamura, C. V. Nakamura, L. B. Garcia, and B. P. D. Filho, "In vitro antifungal activity of the berberine and its synergism with fluconazole," Antonie van Leeuwenhoek, vol. 97, no. 2, pp. 201-205, 2010.
53. D. Yan, C. Jin, X.-H. Xiao, and X.-P. Dong, "Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry," Journal of Biochemical and Biophysical Methods, vol. 70, no. 6, pp. 845-849, 2008.
54. R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, "Microbial ecology: human gut microbes associated with obesity," Nature, vol. 444, no. 7122, pp. 1022-1023, 2006.
55. J. K. DiBaise, H. Zhang, M. D. Crowell, R. Krajmalnik-Brown, G. A. Decker, and B. E. Rittmann, "Gut microbiota and its possible relationship with obesity,"Mayo Clinic Proceedings, vol. 83, no. 4, pp. 460-469, 2008.
56. W. Xie, D. Gu, J. Li, K. Cui, and Y. Zhang, "Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice," PLoS ONE, vol. 6, no. 9, Article ID e24520, 2011.
57. X. Zhang, Y. Zhao, M. Zhang et al., "Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats," PLoS ONE, vol. 7, no. 8, Article ID e42529, 2012.
58. Z. Li, Y. N. Geng, J. D. Jiang, and W. J. Kong, "Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus," Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 289264, 12 pages, 2014.
59. W. Xie and L. Du, "Diabetes is an inflammatory disease: evidence fromtraditionalChinesemedicines," Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 289-301, 2011.
60. J. Singh and P. Kakkar, "Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats," Journal of Ethnopharmacology, vol. 123, no. 1, pp. 22-26, 2009.
61. S. Golbidi and I. Laher, "Antioxidant therapy in human endocrine disorders,"Medical ScienceMonitor, vol. 16, no. 1, pp. RA9-RA24, 2010.
62. J.-Y. Zhou and S.-W. Zhou, "Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver," Fitoterapia, vol. 82, no. 2, pp. 184-189, 2011.
63. P. Bhutada, Y. Mundhada, K. Bansod et al., "Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes," Behavioural Brain Research, vol. 220, no. 1, pp. 30-41, 2011.
64. Y. Wang, T. Campbell, B. Perry, C. Beaurepaire, and L. Qin, "Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats," Metabolism: Clinical and Experimental, vol. 60, no. 2, pp. 298-305, 2011.
65. W.-H. Liu, Z.-Q. Hei, H. Nie et al., "Berberine ameliorates renal injury in streptopzotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase," Chinese Medical Journal, vol. 121, no. 8, pp. 706-712, 2008.
66. T. Lan, X. Shen, P. Liu et al., "Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphKS1P signaling pathway," Archives of Biochemistry and Biophysics, vol. 502, no. 2, pp. 112-120, 2010.
67. W. Liu, P. Liu, S. Tao et al., "Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose," Archives of Biochemistry and Biophysics, vol. 475, no. 2, pp. 128-134, 2008.
68. H. Z. Yang, M. M. Zhou, A. H. Zhao et al., "Study on effects of baicalin, berberine and astragalus polysaccharides and their combinative effects on aldose reductase in vitro," Zhong Yao Cai, vol. 32, no. 8, pp. 1259-1261, 2009.
69. A. Dregan, J. Charlton, P. Chowienczyk, and M. C. Gulliford, "Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study," Circulation, vol. 130, no. 10, pp. 837-844, 2014.
70. H. W. Jeong, K. C. Hsu, M. Ham et al., "Berberine suppresses pro-inflammatory responses through AMPK activation in macrophages," American Journal of Physiology - Endocrinology and Metabolism, vol. 296, no. 4, pp. E955-E964, 2009.
71. T. Lou, Z. Zhang, Z. Xi et al., "Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes," Inflammation, vol. 34, no. 6, pp. 659-667, 2011.
72. Q. Jiang, P. Liu, X. Wu et al., "Berberine attenuates lipopolysaccharide- induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway," Molecular and Cellular Endocrinology, vol. 331, no. 1, pp. 34-40, 2011.
73. Y. Wang, "Attenuation of berberine on lipopolysaccharideinduced inflammatory and apoptosis responses in β-cells via TLR4-independent JNK/NF-κB pathway," Pharmaceutical Biology, vol. 52, no. 4, pp. 532-538, 2014.
74. L.Q. Tang, W. Wei, L. M. Chen, and S. Liu, "Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats," Journal of Ethnopharmacology, vol. 108, no. 1, pp. 109-115, 2006.
75. W. Kong, J. Wei, P. Abidi et al., "Berberine is a novel cholesterollowering drug working through a unique mechanism distinct from statins," Nature Medicine, vol. 10, no. 12, pp. 1344-1351, 2004.
76. W. J. Kong, J. Liu, and J. D. Jiang, "Human low-density lipoprotein receptor gene and its regulation," Journal of Molecular Medicine (Berlin), vol. 84, no. 1, pp. 29-36, 2006.
77. P. Abidi, Y. Zhou, J.-D. Jiang, and J. Liu, "Extracellular signalregulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2170-2176, 2005.
78. Lee S, H. J. Lim, J. H. Park, K. S. Lee, Y. Jang, and H. Y. Park, "Berberine-induced LDLR up-regulation involves JNK pathway," Biochemical and Biophysical Research Communications, vol. 362, no. 4, pp. 853-857, 2007.
79. J.-M. Brusq, N. Ancellin, P. Grondin et al., "Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine," Journal of Lipid Research, vol. 47, no. 6, pp. 1281-1288, 2006.
80. J. Yin, H. Xing, and J. Ye, "Efficacy of berberine in patients with type 2 diabetes mellitus," Metabolism: Clinical and Experimental, vol. 57, no. 5, pp. 712-717, 2008.
81. H. Zhang, J. Wei, R. Xue et al., "Berberine lowers blood glucose in type 2 diabetes mellitus Patients through increasing insulin receptor expression," Metabolism: Clinical and Experimental, vol. 59, no. 2, pp. 285-292, 2010.
82. Y. Zhang, X. Li, D. Zou et al., "Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine," The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 7, pp. 2559-2565, 2008.
83. Z. X. Sheng and D. H. Xie, "Therapeutic effect of berberine on the levels of inflammatory factors in type 2 diabetic patients," New Medicine, vol. 41, no. 3, pp. 177-180, 2010.
84. S. L. Yin, H. Q. Yin, C. H. Li, and C. M. Liu, "The effects of berberine hydrochloride on blood glucose, insulin and lipids levels in newly diagnosed type 2 diabetic patients," Xu Zhou Yi Xue Yuan Xue Bao, vol. 31, no. 1, pp. 40-41, 2011.
85. Z. Li and L.H. Liu, "Therapeutic efficacy of combined berberine and glipizide on type 2 diabetesmellitus," Yi Xue Lin Chuang Za Zhi, vol. 24, no. 1, pp. 61-64, 2007.
86. S. B. Pu, H. X. Xu, Y. H. Zhang et al., "Individual difference of growth condition and alkaloid content of Chinese gold thread (Coptis chinensis)," Zhong Cao Yao, vol. 30, no. 5, pp. 375-377, 1999.
87. Y. P. Zhang, L. Han, Q. H. Yang et al., "Discussion on the medicinal properties and efficacy of berberine," Zhong Guo Yi Yao Ke Xue, vol. 2, no. 21, pp. 52-53, 2012.
88. D. Wu and J. Wei, "Clinical observation on berberine treating type 2 diabetesmellitus," Acta UniversitatisMedicinalis Nanjing, vol. 29, no. 5, pp. 736-738, 2009.
89. H. Tang and Y. Shen, "Clinical study on hypoglycemic effect of berberine on different TCM syndromes of type 2 diabetes," Shang Hai Zhong Yi Yao Za Zhi, vol. 42, no. 12, pp. 22-24, 2008.
90. J. Guo, H. D. Chen, J. Song, J. Wang, L. Zhao, and X. Tong, "Syndrome differentiation of diabetes by the traditional Chinese medicine," Evidence-Based Complementary and Alternative Medicine, vol. 2004, Article ID 492193, 7 pages, 2004.
91. T. Zhang and M. J. Chen, "Research progresses on the antihyperglycemic effect of berberine," Zhong Guo Shi Yong Yi Yao, vol. 4, no. 22, pp. 246-248, 2009.
92. B. Guo and H. X. Zhao, "Hypoglycemic pharmacodynamics and clinical efficacy of berberine," Zhong Guo Yao Ye, vol. 15, no. 21, pp. 30-31, 2006.
93. W. Hua, L. Ding, Y. Chen, B. Gong, J. He, and G. Xu, "Determination of berberine in human plasma by liquid chromatography- electrospray ionization-mass spectrometry," Journal of Pharmaceutical and Biomedical Analysis, vol. 44, no. 4, pp. 931-937, 2007.
94. X. L. Bian, L. C. He, and G. D. Yang, "Synthesis and antihyperglycemic evaluation of various protoberberine derivatives," Bioorganic & Medicinal Chemistry Letters, vol. 16, pp. 1380-1383, 2006.
95. Z. Cheng, A. F. Chen, F. Wu et al., "8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models," Bioorganic & Medicinal Chemistry, vol. 18, no. 16, pp. 5915-5924, 2010.
96. N. Turner, J.-Y. Li, A. Gosby et al., "Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate amp-activated protein kinase and improve insulin action," Diabetes, vol. 57, no. 5, pp. 1414-1418, 2008.
97. V. P. Torchilin, "Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery," Nature Reviews Drug Discovery, vol. 13, no. 11, pp. 813-827, 2014.
98. R. Kapoor, S. Singh, M. Tripathi, P. Bhatnagar, P. Kakkar, and K. C. Gupta, "O-hexadecyl-dextran entrapped berberine nanoparticles abrogate high glucose stress induced apoptosis in primary rat hepatocytes," PLoS ONE, vol. 9, no. 2, Article ID e89124, 2014.
99. S. Pund, G. Borade, and G. Rasve, "Improvement of anti-inflammatory and anti-angiogenic activity of berberine by novel rapid dissolving nanoemulsifying technique," Phytomedicine, vol. 21, no. 3, pp. 307-314, 2014.
100. S. Y. Yang and X. H. Wang, "Discussion between Chinese herbal researches on skin infections of newborn infants and 'jaundice of the newborn baby caused by Rhizoma Coptidis'," Yi Xue Yan Jiu, vol. 37, no. 7, p. 95, 2008.
101. C. L. Liao, Preliminary Observation on Physiological Jaundice (Fetal Jaundice) of the Newborn Baby Related by Yinchen Hao Decoction and Rhizoma Coptidis, vol. 13, Private School of Chinese Medicine Researches of Annual Report, 1982.
102. B. L. Ma, Y. M. Ma, R. Shi et al., "Identification of the toxic constituents in Rhizoma Coptidis," Journal of Ethnopharmacology, vol. 128, no. 2, pp. 357-364, 2010.
103. M. M. Kheir, Y. Wang, L. Hua et al., "Acute toxicity of berberine and its correlation with the blood concentration in mice," Food and Chemical Toxicology, vol. 48, no. 4, pp. 1105-1110, 2010.
104. Q. M. G. Na, T. Y. Zhao, M. He, and C. Tian, "Effectiveness and safety of berberine in the treatment of type 2 diabetes: a systematic review," Zhong Guo Xun Zheng Yi Xue Za Zhi, vol. 12, no. 1, pp. 81-91, 2012.
105. C. Vincent and A. Furnham, "Why do patients turn to complementary medicine? An empirical study," British Journal of Clinical Psychology, vol. 35, no. 1, pp. 37-48, 1996.
106. R. A. Bell, C. K. Suerken, J. G. Grzywacz, W. Lang, S. A. Quandt, and T. A. Arcury, "Complementary and alternative medicine use among adults with diabetes in theUnited States," Alternative Therapies in Health and Medicine, vol. 12, no. 5, pp. 16-22, 2006.
107. M.-S. Lee, M. S. Lee, H.-J. Lim, and S.-R. Moon, "Survey of the use of complementary and alternative medicine among Korean diabetes mellitus patients," Pharmacoepidemiology and Drug Safety, vol. 13, no. 3, pp. 167-171, 2004.
108. X. Tu, C. G. Xie, F. Wang et al., "Fructus mume formula in the treatment of type 2 diabetes mellitus: a randomized controlled pilot trial," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 787459, 8 pages, 2013.